Direct-to-Consumer (DTC) Genetic Testing Market Size

Direct-to-Consumer Genetic Testing Market Size

Direct-to-Consumer Genetic Testing Market size surpassed USD 3 billion in 2022 and is predicted to expand at over 11.5% CAGR from 2023-2032. Rising prevalence of genetic disorders will accelerate industry growth.

To get key market trends

  Download Free Sample

A dramatic rise in the incidences of genetic disorders such as cystic fibrosis, Sickle cell disease, Alzheimer’s disease (AD), and some cancers is expected to proliferate the demand for DTC genetic tests. For instance, as per the 2022 report by the National Institute of Health (NIH), nearly 6.5 million people above 65 years of age in the U.S. have AD-related dementia and the patient pool is estimated to exceed 13.5 million by 2060 in case of a dearth in medical breakthroughs.

The increasing focus on customized healthcare solutions has fostered the substantial demand for personalized DTC genetic tests, particularly across developing countries with burgeoning medical needs. Additionally, leading industry players are implementing strategic deals to provide modern testing services on online platforms with improved accessibility. For instance, in October 2021, 23andMe announced plans to acquire Lemonaid Health, a virtual healthcare, and pharmacy platform to combine personalized genetics services and primary care.

High pricing model of DTC kits may impede product demand

High costs associated with DTC genetic testing services could hamper the direct-to-consumer genetic testing market outlook. A large number of manufacturers are focusing on product innovations and integration of next-generation technologies to introduce high-end DTC tests, leading to higher product pricing. For instance, based on the complexity of the test and severity of the disease, the cost of DTC genetic tests varies from USD 100 to USD 3,000. Hence, the demand for genetic services across underdeveloped and developing regions could potentially reduce with affordability issues.